Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 11, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its
View HTML
Toggle Summary Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer
Data support use of Afirma Xpression Atlas to inform surgery and treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 3, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data that further define the genomic landscape around thyroid
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the following upcoming investor conferences: 2019 Wells Fargo Healthcare Conference , Boston Presentation on
View HTML
Toggle Summary Veracyte Announces Second Quarter 2019 Financial Results
Revenue Grew 32% to $30.1 Million Genomic Test Volume Grew 26% to 9,663 Company Raises 2019 Full-Year Revenue Guidance Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for
View HTML
Toggle Summary Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer
Expanded Role Strengthens Top Tier of Company’s Executive Leadership Team SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Keith Kennedy , the company’s current chief financial
View HTML
Toggle Summary Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis
Genomic Test is Veracyte’s First Commercial Product to Emerge Since Entering into Strategic Collaboration with Johnson & Johnson Innovation SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 26, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it
View HTML
Toggle Summary Veracyte Named a San Francisco Bay Area “Top Workplace” For Sixth Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 24, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the company has been awarded a Top Workplaces 2019 honor by the Bay Area News Group for the sixth consecutive year.
View HTML
Toggle Summary Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
- Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that a review article in Cancer Cytopathology , a journal of the American Cancer
View HTML
Toggle Summary Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma ® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce
View HTML